The FDA has expanded the approval for pembrolizumab monotherapy for the frontline treatment of patients with stage III non–small cell lung cancer, who are ineligible for surgery or definitive chemoradiation, or metastatic NSCLC, with a PD-L1 expression (tumor proportion score) level of ≥1% and do not harbor EGFR or ALK aberrations.
Kimberly Cannavale, MPH, discusses a study of the association between Charlson comorbidity index and complete remission in patients with ovarian cancer.
Ankit Mangla, MD, expands on key survival data from the phase 2/3 RELATIVITY-047 trial in previously untreated, unresectable, or metastatic melanoma.
Ritu Salani, MD, discusses the development of ADCs, the potential role of selinexor, and the use of PARP inhibitors across endometrial cancer subsets.
An NDA has been submitted to the FDA for TLX101-CDx for the characterization of progressive or recurrent glioma in adult and pediatric patients.
The FDA has granted fast track designation to IBI363 for unresectable advanced or metastatic melanoma after progression on at least 1 line of therapy.
OncLive serves as the connection to oncology, including groundbreaking cancer news and interviews with top oncologists in multimedia formats.
The phase 3 IOB-013/KN-D18 trial of IO102-IO103 plus pembrolizumab in advanced melanoma will continue without modifications.
Drs Armstrong and Tawagi discuss high-yield oncology and hematology topics to focus on when studying for the 2024 oncology board exams.
A panel of experts offer future perspectives in HR+ breast cancer.
OncLive serves as the connection to oncology, including groundbreaking cancer news and interviews with top oncologists in multimedia formats.
